NASDAQ:SYNH - Syneos Health Stock Price, Forecast & News

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

Syneos Health Inc (NASDAQ:SYNH) released its quarterly earnings data on Thursday, February, 20th. The company reported $1.03 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.01 by $0.02. The firm had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.19 billion. Syneos Health had a net margin of 2.81% and a return on equity of 10.12%. The company's revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.95 EPS. View Syneos Health's Earnings History.

Syneos Health is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Syneos Health.

Syneos Health updated its FY20 earnings guidance on Thursday, February, 20th. The company provided earnings per share (EPS) guidance of $3.58-3.78 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.65. The company issued revenue guidance of $4.88-5.00 billion, compared to the consensus revenue estimate of $4.94 billion.

11 brokerages have issued 12-month target prices for Syneos Health's shares. Their forecasts range from $65.00 to $82.00. On average, they anticipate Syneos Health's share price to reach $71.22 in the next year. This suggests a possible upside of 13.5% from the stock's current price. View Analyst Price Targets for Syneos Health.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syneos Health.

News coverage about SYNH stock has been trending somewhat negative this week, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Syneos Health earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Syneos Health.

Some companies that are related to Syneos Health include Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Icon (ICLR), Charles River Laboratories Intl. (CRL), PRA Health Sciences (PRAH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Sorrento Therapeutics (SRNE), STARPHARMA HOLD/S (SPHRY), Auxly Cannabis Group (CBWTF) and Anavex Life Sciences (AVXL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include AT&T (T), NVIDIA (NVDA), CVS Health (CVS), UnitedHealth Group (UNH), Icon (ICLR), Jazz Pharmaceuticals (JAZZ), Netflix (NFLX), Skyworks Solutions (SWKS), Alibaba Group (BABA) and Iqvia (IQV).

Syneos Health's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (2.23%), State Street Corp (1.92%), Bank of New York Mellon Corp (1.51%), Goldman Sachs Group Inc. (1.44%), Boston Partners (1.25%) and GW&K Investment Management LLC (1.05%). Company insiders that own Syneos Health stock include Alistair Macdonald, H Lee Equity Fund Vi Thomas, Jason M Meggs and Jonathan Olefson. View Institutional Ownership Trends for Syneos Health.

SYNH stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Principal Financial Group Inc., Prudential Financial Inc., Sei Investments Co., AXA, Goldman Sachs Group Inc., Boston Partners and Rothschild & Co. Asset Management US Inc.. View Insider Buying and Selling for Syneos Health.

SYNH stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Jennison Associates LLC, Hennessy Advisors Inc., Barclays PLC, Knights of Columbus Asset Advisors LLC, Hawk Ridge Capital Management LP, ArrowMark Colorado Holdings LLC and Magnetar Financial LLC. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs and Jonathan Olefson. View Insider Buying and Selling for Syneos Health.

Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SYNH stock can currently be purchased for approximately $62.74.

Syneos Health has a market capitalization of $6.54 billion and generates $4.68 billion in revenue each year. The company earns $131.26 million in net income (profit) each year or $2.83 on an earnings per share basis. Syneos Health employs 24,000 workers across the globe.View Additional Information About Syneos Health.

The official website for Syneos Health is http://www.syneoshealth.com/.

Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The company can be reached via phone at 919-876-9300 or via email at [email protected]